Infliximab has a strong binding affinity toward soluble TNF (sTNF) and transmembrane TNF (tmTNF) but very weak binding affinity to LT ligands. This drug has very strong actions toward apoptosis, cytokine suppression, CDC, and ADCC. Similar to infliximab, the drug Adalimumab has strong binding affinity toward sTNF and tmTNF and very weak binding affinity toward LT ligands. This drug also has very strong actions toward apoptosis, cytokine suppression, CDC, and ADCC. Etanercept has very strong binding affinity to both TNF ligands as well as the two LT ligands of LT3 and LT21. This drug only has moderate to very weak actions toward reverse signaling, CDC, and ADCC. The last drug, Certilizumab, only has strong binding affinity toward the two TNF ligands. The drug has very strong actions toward cytokine suppression, however very weak actions toward apoptosis, CDC, and ADCC.
Infliximab has a strong binding affinity toward soluble TNF (sTNF) and transmembrane TNF (tmTNF) but very weak binding affinity to LT ligands. This drug has very strong actions toward apoptosis, cytokine suppression, CDC, and ADCC. Similar to infliximab, the drug Adalimumab has strong binding affinity toward sTNF and tmTNF and very weak binding affinity toward LT ligands. This drug also has very strong actions toward apoptosis, cytokine suppression, CDC, and ADCC. Etanercept has very strong binding affinity to both TNF ligands as well as the two LT ligands of LT3 and LT21. This drug only has moderate to very weak actions toward reverse signaling, CDC, and ADCC. The last drug, Certilizumab, only has strong binding affinity toward the two TNF ligands. The drug has very strong actions toward cytokine suppression, however very weak actions toward apoptosis, CDC, and ADCC.